Nektar Therapeutics (NKTR) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free NKTR Stock Alerts $1.27 +0.01 (+0.79%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 6:00 PM | prnewswire.comNektar Management to Present at Upcoming Investor ConferencesMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)May 21, 2024 | insidertrades.comJonathan Zalevsky Sells 7,355 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockMay 21, 2024 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 16,650 Shares of StockMay 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Cuts Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)Assenagon Asset Management S.A. reduced its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 31.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,687,300 shares of the biopharmaceMay 19, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Hold" by AnalystsNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned aMay 14, 2024 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Major Shareholder Sells 56,000 Shares of StockMay 11, 2024 | marketbeat.comMonaco Asset Management SAM Buys 1,163,786 Shares of Nektar Therapeutics (NASDAQ:NKTR)Monaco Asset Management SAM grew its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,973,387 shares of theMay 11, 2024 | uk.finance.yahoo.comQ1 2024 Nektar Therapeutics Earnings CallMay 11, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $21.64 million for the quarter, compared to the consensus estimate of $14.91 million. Nektar Therapeutics had a negative net margin of 195.02% and a negative return on equity of 101.41%. During the same quarter in the previous year, the company earned ($0.25) earnings per share.May 10, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) First Quarter 2024 Earnings OverviewMay 10, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024May 9, 2024 | markets.businessinsider.comNektar Therapeutics Q1 Loss Drops In Line With EstimatesMay 9, 2024 | washingtonpost.comNektar: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comNektar Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Nektar Therapeutics's earningsMay 3, 2024 | marketbeat.comNektar Therapeutics (NKTR) Scheduled to Post Quarterly Earnings on ThursdayNektar Therapeutics (NASDAQ:NKTR) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | prnewswire.comNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsApril 24, 2024 | globenewswire.comBiolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune DiseasesApril 20, 2024 | finance.yahoo.comNatural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline DrugsApril 20, 2024 | investing.comNektar regains Nasdaq compliance with bid priceApril 10, 2024 | seekingalpha.comNektar Therapeutics Sees Something In The Data And Puts Its Drug To The TestApril 1, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sees Large Growth in Short InterestNektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,510,000 shares, a growth of 24.9% from the February 29th total of 2,010,000 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 1.6 days.March 29, 2024 | yahoo.com“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD setMarch 22, 2024 | prnewswire.comNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 10, 2024 | marketbeat.comGSA Capital Partners LLP Increases Position in Nektar Therapeutics (NASDAQ:NKTR)GSA Capital Partners LLP lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 931.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,841,078 shares of the biopharmaceutical company's stock after buying an additional 1,662March 7, 2024 | marketbeat.comWilliam Blair Equities Analysts Reduce Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at William Blair decreased their Q1 2024 earnings estimates for Nektar Therapeutics in a report issued on Tuesday, March 5th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will earn ($0.22) per sMarch 6, 2024 | marketbeat.comNektar Therapeutics to Post FY2026 Earnings of ($1.05) Per Share, William Blair Forecasts (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for Nektar Therapeutics in a report issued on Tuesday, March 5th. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will post earMarch 5, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | marketbeat.comNektar Therapeutics' (NKTR) Market Perform Rating Reaffirmed at William BlairWilliam Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research report on Tuesday.March 5, 2024 | finance.yahoo.comQ4 2023 Nektar Therapeutics Earnings CallMarch 5, 2024 | prnewswire.comNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataMarch 5, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Average Rating of "Hold" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average recommendation of "Hold" from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation anMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Q4 Loss decreases, but misses estimatesMarch 4, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 ResultsMarch 4, 2024 | prnewswire.comNektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In PremarketMarch 4, 2024 | prnewswire.comNektar Therapeutics Announces $30 Million Private Placement Financing with TCGXMarch 3, 2024 | markets.businessinsider.comNektar Therapeutics earnings: here's what Wall Street expectsMarch 1, 2024 | benzinga.comNektar Therapeutics Earnings PreviewFebruary 27, 2024 | prnewswire.comNektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | marketbeat.comLynx1 Capital Management LP Takes $1.05 Million Position in Nektar Therapeutics (NASDAQ:NKTR)Lynx1 Capital Management LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,766,815 shares of the biopFebruary 26, 2024 | prnewswire.comNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsFebruary 24, 2024 | marketbeat.comAcadian Asset Management LLC Acquires 3,230,368 Shares of Nektar Therapeutics (NASDAQ:NKTR)Acadian Asset Management LLC lifted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 73.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,626,388 shares of the biopharmaceutical company's stock after purchasing an additionaFebruary 23, 2024 | msn.comNektar to play final UK live show at Nene Valley Rock festival in SeptemberFebruary 22, 2024 | msn.comEuro zone bond yields dip, data shows wage growth slowed in Q4February 22, 2024 | benzinga.comNektar Therapeutics Stock (NASDAQ:NKTR) Insider TradesFebruary 20, 2024 | finance.yahoo.comWill Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should KnowFebruary 19, 2024 | marketbeat.comEquities Analysts Offer Predictions for Nektar Therapeutics' Q1 2024 Earnings (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Analysts at Zacks Research boosted their Q1 2024 EPS estimates for Nektar Therapeutics in a note issued to investors on Thursday, February 15th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings pe Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. NKTR Media Mentions By Week NKTR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.680.76▲Average Medical News Sentiment NKTR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼32▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADCT News Today AVIR News Today OMER News Today MCRB News Today ASMB News Today CPIX News Today ALXO News Today AGIO News Today ALKS News Today KRTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
